Table 1.
General and clinical characteristics of 1666 patients.
| Not Vaccinated (n = 1103 − 65.4%) |
Vaccinated with One Dose (n = 92 − 5.5%) |
Vaccinated with Two Doses or Monodose (n = 321 − 19%) |
Vaccinated with Three Doses (n = 170 − 10.1%) |
p-Value | |
|---|---|---|---|---|---|
| Demographic and Clinical Data | |||||
| Age (years) | 63 (26) | 71 (24.5) | 73 (24) | 75 (19) | <<0.001 |
| Sex | 0.63 | ||||
| M | 613 (55.6%) | 50 (54.3%) | 191 (59.5%) | 95 (55.9%) | |
| F | 490 (44.4%) | 42 (45.7%) | 130 (40.4%) | 75 (44.1%) | |
| Vaccine type | - | ||||
| mRNA | 79 (85.9%) | 251 (78.2%) | 151 (88.8%) | ||
| 13 (14.1%) | 65 (20.2%) | - | |||
| Adenovirus | |||||
| mixed | 5 (1.6%) | 19 (11.2%) | |||
| Comorbidities | |||||
| Diabetes | 176 (15.9%) | 11 (11.9%) | 44 (13.7%) | 18 (10.6%) | 0.22 |
| COPD | 58 (5.2%) | 12 (13%) | 25 (7.8%) | 16 (9.4%) | 0.006 |
| Hypertension | 317 (28.7%) | 22 (23.9%) | 93 (28.9%) | 37 (21.7%) | 0.21 |
| CHD | 106 (9.6%) | 6 (6.5%) | 39 (12.1%) | 27 (15.9%) | 0.03 |
| CLD | 31(2.8%) | 3 (3.3%) | 17 (5.3%) | 6 (3.5%) | 0.19 |
| CKD | 90 (8.2%) | 4 (4.3%) | 52 (16.2%) | 34 (20%) | <<0.001 |
| Cancer | 63 (5.7%) | 12 (13%) | 34 (10.6%) | 35 (20.6%) | <<0.001 |
| Dementia | 28 (2.5%) | 4 (4.3%) | 16 (4.9%) | 13 (7.6%) | 0.004 |
| CVD | 65 (5.9%) | 5 (5.4%) | 51 (15.9%) | 30 (17.6%) | <<0.001 |
| Time (days) vaccination-admission (days) |
- | 21.31 (48.10) | 174.16 (92.81) | 45.62 (56.73) | <<0.001 |
| Laboratory Data | |||||
| Lymphocytes, 103 | 0.6 (0.6) | 0.6 (0.6) | 0.7 (0.7) | 0.6 (0.66) | 0.02 |
| Platelets, 103 | 178 (105) | 156.5 (89.75) | 165 (103) | 161.5 (106.75) | <<0.001 |
| Neutrophils, 103 | 85.87 (13.12) | 85.45 (14.32) | 84 (16.2) | 87.29 (13.86) | 0.003 |
| Creatinine, | 0.88 (0.43) | 0.93 (0.52) | 1.08 (0.66) | 1.16 (1.01 | <<0.001 |
| CRP, | 9.97 (12.61) | 10.92 (12.31) | 9.65 (13.89) | 7.33 (14.52) | 0.46 |
| PCTI, | 0.17 (0.82) | 0.19 (0.87) | 0.32 (1.71) | 0.68 (3.2) | <<0.001 |
| DD, | 1822 (3948) | 1810 (3392) | 1949 (5657) | 2099 (3934) | 0.52 |
| Glucose, | 112 (52) | 108.5 (38.25) | 113 (52.2) | 121 (63) | 0.1 |
| TNI, | 14 (58.5) | 39 (81.25) | 28.5 (176.25) | 76.5 (519.25) | <<0.001 |
| Clinical Outcomes | |||||
| Death | 144 (13.1%) | 17 (18.5%) | 63 (19.6%) | 32 (18.8%) | 0.01 |
| Oxygen required | |||||
| CPAP | 392 (35.3%) | 27 (29.3%) | 66 (20.5%) | 25 (14.7%) | <<0.001 |
| ETI | 94 (8.5%) | 8 (8.7%) | 9 (2.8%) | - | <0.001 |
| ILOS (days) | 12.31 (14.13) | 12.41 (14.54) | 10.09 (14.09) | 11.14 (13.93) | 0.02 |
| ICU admitted | |||||
| yes | 267 (24.2%) | 15 (16.3%) | 22 (6.8%) | 14 (8.2%) | <<0.001 |
| ICU-LOS (days) | 12.98 (21.22) | 13.28 (23.54) | 12.52 (31.97) | 6.95 (5.55) | <<0.001 |
COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease; CLD, chronic liver disease; CKD, chronic kidney disease; CVD, cerebrovascular disease; CPAP, continuous positive airways pressure; ETI, endotracheal intubation; ICU, intensive care unit; LOS, length of stay; DD: D-dimer; PCT: procalcitonin; CRP: C-reactive protein; TNI: troponin.